PH16474A - Clavulcanic acid,salts and esters thereof and pharmaceutical compositions containing same - Google Patents

Clavulcanic acid,salts and esters thereof and pharmaceutical compositions containing same

Info

Publication number
PH16474A
PH16474A PH17082A PH17082A PH16474A PH 16474 A PH16474 A PH 16474A PH 17082 A PH17082 A PH 17082A PH 17082 A PH17082 A PH 17082A PH 16474 A PH16474 A PH 16474A
Authority
PH
Philippines
Prior art keywords
clavulcanic
esters
salts
acid
pharmaceutical compositions
Prior art date
Application number
PH17082A
Other languages
English (en)
Inventor
Martin Cole
Thomas Trefor Howarth
Christopher Reading
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27448389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH16474(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB17410/74A external-priority patent/GB1508977A/en
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of PH16474A publication Critical patent/PH16474A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D503/00—Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PH17082A 1974-04-20 1975-04-21 Clavulcanic acid,salts and esters thereof and pharmaceutical compositions containing same PH16474A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB17410/74A GB1508977A (en) 1974-04-20 1974-04-20 Beta-lactam antibiotic from streptomyces clavuligerus
GB2771574 1974-06-21
GB4365174 1974-10-09
GB5352574 1974-12-11

Publications (1)

Publication Number Publication Date
PH16474A true PH16474A (en) 1983-10-25

Family

ID=27448389

Family Applications (1)

Application Number Title Priority Date Filing Date
PH17082A PH16474A (en) 1974-04-20 1975-04-21 Clavulcanic acid,salts and esters thereof and pharmaceutical compositions containing same

Country Status (26)

Country Link
US (5) US4427690A (ro)
JP (7) JPS5246957B2 (ro)
AR (3) AR206627A1 (ro)
CA (1) CA1059050A (ro)
CH (2) CH629252A5 (ro)
CY (1) CY1078A (ro)
DD (2) DD121799A5 (ro)
DE (4) DE2560074C2 (ro)
DK (1) DK141254B (ro)
FI (1) FI54144C (ro)
FR (1) FR2267778B1 (ro)
HK (1) HK54780A (ro)
IE (1) IE41109B1 (ro)
IL (1) IL47087A (ro)
IN (1) IN140042B (ro)
KE (1) KE3076A (ro)
LU (1) LU72322A1 (ro)
MY (1) MY8100195A (ro)
NL (1) NL163824C (ro)
NO (3) NO145247C (ro)
NZ (1) NZ177159A (ro)
OA (1) OA05203A (ro)
PH (1) PH16474A (ro)
RO (2) RO69984A (ro)
SE (8) SE422063B (ro)
YU (3) YU39941B (ro)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE41109B1 (en) 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
SE421796B (sv) * 1975-02-07 1982-02-01 Glaxo Lab Ltd Forfarande for rening av klavulansyra och dess salter
JPS596796Y2 (ja) * 1975-04-04 1984-03-01 株式会社東芝 脱水兼用洗濯機
US6031093C1 (en) * 1975-04-17 2001-10-16 Smithkline Beecham Plc Solid salts of clavulanic acid
US6218380B1 (en) * 1975-04-17 2001-04-17 Smithkline Beecham P.L.C. Pharmaceutical compositions
GB1563103A (en) * 1975-10-13 1980-03-19 Beecham Group Ltd Process for the preparation of clavulanic acid
US4230622A (en) * 1975-12-17 1980-10-28 Glaxo Laboratories Limited Halogen derivatives of clavulaic acid
GB1515241A (en) * 1976-01-27 1978-06-21 Beecham Group Ltd Beta-lactam antibiotics
DK250477A (da) * 1976-06-08 1977-12-09 Glaxo Lab Ltd Fremgangsmade til fremstilling af clavamforbindelser
GB1562802A (en) * 1976-06-26 1980-03-19 Beecham Group Ltd Pharmaceutical compositions containing containing clavulanic acid
GB1562902A (en) * 1976-06-30 1980-03-19 Beecham Group Ltd Pharmaceutical compositions containing clavulanic acid
GB1578739A (en) * 1976-07-23 1980-11-05 Beecham Group Ltd Amine salts of clavulanic acid methods for their preparation and compositions containing them
GB1594001A (en) * 1977-03-16 1981-07-30 Beecham Group Ltd Pellets suitable for use in the testing of microorganisms
GB1582884A (en) * 1977-05-19 1981-01-14 Beecham Group Ltd Clavulanic acid derivatives their preparation and use
DE2912511C2 (de) * 1977-06-07 1982-06-24 Pfizer Inc., 10017 New York, N.Y. Pharmazeutische Zusammensetzung, enthaltend Penicillansäure
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
JPS54126735A (en) * 1978-03-24 1979-10-02 Toyama Chem Co Ltd Bactericidal composition for medical use
DE2964817D1 (en) * 1978-09-06 1983-03-24 Beecham Group Plc Pharmaceutical compositions containing two beta-lactam derivatives
JPS5545906U (ro) * 1978-09-21 1980-03-26
US4202819A (en) * 1979-05-04 1980-05-13 Hoffman-La Roche Inc. 2-(3-Alanyl)clavam antibiotic
ZA804670B (en) * 1979-08-03 1981-07-29 Beecham Group Ltd Derivatives of clavulanic acid, a process for their preparation and their use
DE3063683D1 (en) * 1979-08-24 1983-07-14 Beecham Group Plc Amine salt of clavulanic acid, its preparation and use
NZ199061A (en) * 1980-12-09 1984-10-19 Beecham Group Ltd 9-(n-tetrazolyl)-deoxyclavulanic acids,salts,esters,and pharmaceutical compositions
NZ199200A (en) * 1980-12-23 1984-07-31 Beecham Group Ltd Clavulanic acid derivatives and pharmaceutical compositions
JPS58361A (ja) * 1981-06-22 1983-01-05 Kurosaki Refract Co Ltd 溶融金属鋳造用ノズル
US4684643A (en) * 1983-08-22 1987-08-04 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
US4533542A (en) * 1983-08-22 1985-08-06 Eli Lilly And Company Pharmaceutical compositions for storage in plastic containers and process therefor
IT1207982B (it) * 1983-10-07 1989-06-01 Lisapharma Spa Composizioni farmaceutiche adattivita' antibiotica.
JPS60151610U (ja) * 1984-03-22 1985-10-08 住友重機械工業株式会社 回転ホイ−ル式連続金属押出装置におけるアバツトメント
JPS6155889A (ja) * 1984-08-28 1986-03-20 松下電器産業株式会社 高周波加熱装置
US4757066A (en) * 1984-10-15 1988-07-12 Sankyo Company Limited Composition containing a penem or carbapenem antibiotic and the use of the same
DE3725375A1 (de) * 1987-07-31 1989-02-09 Bayer Ag Stabile oxapenem-3-carbonsaeuren
GB9009446D0 (en) * 1990-04-26 1990-06-20 Beecham Group Plc Veterinary composition
DE4027928A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Neue 2-tert.substituierte methyl-oxapenem-3-carbonsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung
DE4030706A1 (de) * 1990-09-28 1992-04-02 Bayer Ag Neue 3-substituierte cephalosporine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9201639D0 (en) * 1992-01-25 1992-03-11 Smithkline Beecham Plc Pharmaceutical formulations
AT400033B (de) * 1992-03-10 1995-09-25 Biochemie Gmbh Neues verfahren zur isolierung und reinigung von clavulansäure und zur herstellung von pharmakologisch verträglichen salzen derselben
AT399155B (de) * 1992-03-26 1995-03-27 Lek Tovarna Farmacevtskih Neue alkylendiammonium-diclavulanat-derivate, verfahren zu deren herstellung sowie deren verwendung
EP0680322B1 (en) * 1993-01-22 2000-07-05 Smithkline Beecham Plc Use of clavulanate and an antibacterial compound for the treatment of infections
AU682030B2 (en) * 1993-03-26 1997-09-18 Dsm N.V. Diamine salts of clavulanic acid
US5821364A (en) * 1993-03-26 1998-10-13 Gist-Brocades N.V. Diamine salts of clavulanic acid
US5741903A (en) * 1993-03-26 1998-04-21 Gist-Brocades N.V. Diamine salts for purification of clavulanic acid
US5760218A (en) * 1993-03-26 1998-06-02 Gist-Brocades N.V. Diamine salts of clavulanic acid
US20030219867A1 (en) * 1993-07-24 2003-11-27 Smithkline Beecham Plc Clavulanic acid dehydrogenase, preparation and use for the production of clavulanic acid
GB9315393D0 (en) * 1993-07-24 1993-09-08 Smithkline Beecham Plc Novel product
SI9400107A (en) * 1994-03-02 1995-10-31 Lek Tovarna Farmacevtskih New process of the isolation of clavulanic acid and its pharmaceutical salts from fermented broth of streptomyces sp.p 6621 ferm p 2804.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
GB9515809D0 (en) * 1995-08-02 1995-10-04 Smithkline Beecham Plc Process
SI9500265A1 (en) 1995-08-28 1997-02-28 Lek Tovarna Farmacevtskih Process for purification of the aqueous fermented broth filtrate of streptomyces sp. p 6621 ferm p 2804 by ultrafiltration
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
AT403375B (de) * 1995-11-15 1998-01-26 Biochemie Gmbh Verfahren zur fällung von alkalisalzen der clavulansäure
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
ATE327340T1 (de) * 1997-02-20 2006-06-15 Dsm Ip Assets Bv Fermentative herstellung von wertstoffen in industriellem umfang durch verwendung von chemisch definierten media
AR015825A1 (es) * 1997-05-28 2001-05-30 Gist Brocades Bv Produccion fermentativa de acido clavulanico bajo condiciones controladas de fosfato
EP1097238A1 (en) * 1998-07-03 2001-05-09 Dsm N.V. Fermentation process to produce clavulanic acid at a low concentration of free amino acids
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1658034A4 (en) 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US20060194285A1 (en) * 2005-02-08 2006-08-31 Wei Lian Biological production of clavulanic acid and related compounds
DE102005009277B4 (de) * 2005-02-25 2008-07-31 Johnson Controls Interiors Gmbh & Co. Kg Halterung für eine Komponente
PT2308874E (pt) * 2005-12-07 2013-04-26 Basilea Pharmaceutica Ag Monobactamas ligadas por pontes, úteis como inibidores de beta-lactamase
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US20070218038A1 (en) 2006-03-17 2007-09-20 Pegasus Biologics, Inc. Stabilized, sterilized collagen scaffolds with active adjuncts attached
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2011152809A2 (en) 2010-06-03 2011-12-08 Bilgic Mahmut Effervescent formulations comprising cephalosporin and clavulanic acid
WO2014089365A1 (en) 2012-12-07 2014-06-12 Venatorx Pharmaceuticals, Inc Beta-lactamase inhibitors
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20190039137A (ko) 2016-07-14 2019-04-10 아카오젠, 인코포레이티드 박테리아 감염 치료에서 사용하기 위한 세프티부텐과 클라불란산의 조합
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
CN114846332A (zh) 2019-10-25 2022-08-02 仪器实验室公司 与酶生物传感器相容的杀生物剂组合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3801464A (en) 1972-02-09 1974-04-02 Lilly Co Eli Antibiotic a16886 and process for production thereof
IE41109B1 (en) * 1974-04-20 1979-10-24 Beecham Group Ltd Novel -lactam antibiotic from streptomyces clavuligerus
US4140764A (en) * 1974-12-18 1979-02-20 Beecham Group Limited β-Lactamase inhibitors and process for their preparation
US4123540A (en) * 1974-12-18 1978-10-31 Beecham Group Limited Isoclavulanic acid as an antibacterial and a β-lactamase inhibitor
SE421796B (sv) * 1975-02-07 1982-02-01 Glaxo Lab Ltd Forfarande for rening av klavulansyra och dess salter
US4144242A (en) * 1975-02-07 1979-03-13 Glaxo Laboratories Limited Process for the purification of clavulanic acid
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration

Also Published As

Publication number Publication date
JPS533590A (en) 1978-01-13
US4556559A (en) 1985-12-03
IN140042B (ro) 1976-09-04
SE8306328L (sv) 1983-11-16
SE8105829L (sv) 1981-10-02
YU39941B (en) 1985-06-30
JPS532495A (en) 1978-01-11
FR2267778A1 (ro) 1975-11-14
JPS5549831B2 (ro) 1980-12-15
YU42745B (en) 1988-12-31
NO791956L (no) 1975-10-21
US4560552A (en) 1985-12-24
SE7811202L (sv) 1978-10-27
SE453600B (sv) 1988-02-15
JPS521996B2 (ro) 1977-01-19
SE7811203L (sv) 1978-10-27
IL47087A0 (en) 1975-06-25
DE2517316A1 (de) 1975-10-23
DD132297A5 (de) 1978-09-20
SE7504541L (ro) 1975-10-18
IE41109L (en) 1975-10-20
DE2560074C2 (de) 1985-03-28
CY1078A (en) 1980-12-27
YU90875A (en) 1982-05-31
RO69984A (ro) 1980-12-30
KE3076A (en) 1980-10-03
US4560552C1 (en) 2001-10-16
DE2559410A1 (de) 1976-09-23
JPS5549830B2 (ro) 1980-12-15
YU274381A (en) 1983-06-30
CA1059050A (en) 1979-07-24
DE2559411C2 (de) 1982-07-01
DK167275A (ro) 1975-10-21
DK141254C (ro) 1980-08-11
DE2559411A1 (de) 1976-10-21
CH629252A5 (de) 1982-04-15
NL163824C (nl) 1980-10-15
SE435286B (sv) 1984-09-17
US4427690A (en) 1984-01-24
AR216430A1 (es) 1979-12-28
SE7811200L (sv) 1978-10-27
DD121799A5 (ro) 1976-08-20
SE443562B (sv) 1986-03-03
DK141254B (da) 1980-02-11
NO801852L (no) 1975-10-21
NZ177159A (en) 1978-03-06
NO751407L (ro) 1975-10-21
YU274481A (en) 1983-06-30
JPS50142591A (ro) 1975-11-17
US4525352A (en) 1985-06-25
NO150838B (no) 1984-09-17
MY8100195A (en) 1981-12-31
SE8605405D0 (sv) 1986-12-16
FI54144B (fi) 1978-06-30
US4526783A (en) 1985-07-02
YU42744B (en) 1988-12-31
CH630631A5 (de) 1982-06-30
NO150838C (no) 1985-01-09
RO77320A (ro) 1981-08-17
SE435287B (sv) 1984-09-17
HK54780A (en) 1980-10-03
JPS533589A (en) 1978-01-13
OA05203A (fr) 1981-02-28
JPS532494A (en) 1978-01-11
NL7504621A (nl) 1975-10-22
JPS5549832B2 (ro) 1980-12-15
FI751133A (ro) 1975-10-21
FR2267778B1 (ro) 1978-11-17
AR219050A1 (es) 1980-07-31
SE7811201L (sv) 1978-10-27
DE2517316C2 (de) 1985-03-07
IL47087A (en) 1979-07-25
FI54144C (fi) 1978-10-10
SE8306328D0 (sv) 1983-11-16
LU72322A1 (ro) 1975-08-20
SE446687B (sv) 1986-10-06
NL163824B (nl) 1980-05-16
SE422063B (sv) 1982-02-15
SE8605405L (sv) 1986-12-16
JPS50142789A (ro) 1975-11-17
IE41109B1 (en) 1979-10-24
JPS5246957B2 (ro) 1977-11-29
NO145247B (no) 1981-11-02
JPS5549833B2 (ro) 1980-12-15
AR206627A1 (es) 1976-08-06
JPS533588A (en) 1978-01-13
NO145247C (no) 1982-02-10

Similar Documents

Publication Publication Date Title
PH16474A (en) Clavulcanic acid,salts and esters thereof and pharmaceutical compositions containing same
IL48642A (en) 3-amino-indazolecarboxylic acid derivatives,ther preparation and pharmaceutical compositions containing them
IL49095A (en) 1,4dihydropyridine-3,5-di-carboxylic acid aralkyl esters their preparation and pharmaceutical compositions containing them
IL52258A (en) Monic acid esters,their preparation and pharmaceutical compositions containing them
IL47860A0 (en) Novel 5,9 beta-disubstituted 2-tetrahydrofuryl-6,7-benzomorphans and their salts,their production and pharmaceutical compositions containing them
IL47360A (en) -amino- and -formyl- -(p-acycloxyphenyl) acetamido-3-cephem-4-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL48707A0 (en) Novel phenylacetic acid derivatives,their preparation and pharmaceutical compositions containing them
IL46539A0 (en) Esters of dihydroapovincaminic acid,their preparation and pharmaceutical compositions containing them
IL46906A0 (en) Beta-aminocrotonic acid esters,their preparation and their use as metamorphosis inhibitors
IL47149A0 (en) New amino acid derivatives,their preparation and pharmaceutical compositions containing them
IL47590A (en) Desoxyvincaminic acid and apovincaminic acid amides,their preparation and pharmaceutical compositions containing them
IL46543A0 (en) New phenoxyalkyl-carboxylic acid derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
IL47299A (en) 3-thiomethyl-3-cephem-4-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL47103A0 (en) 5-oxo-5h-dibenzo(a,d)-cycloheptene-2-acetic acid derivatives and salts and esters,their preparation and pharmaceutical compositions containing them
IL50644A (en) 12-aza-11-oxo-15-hydroxyprostanoic acid analogues,their preparation and pharmaceutical compositions containing them
IL47519A (en) 7-sulphinimidoyl(sulphimidoyl)-xanthone-2-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
IL47104A0 (en) 2-carboxy-5-oxo-5h-dibenzo(a,d)cycloheptenes,their salts and esters,their preparation and pharmaceutical compositions containing them
IL47606A (en) 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4h-1-benzopyran-2-carboxylic acid and salts, esters or amides thereof, their preparation and pharmaceutical compositons containing them
IL48617A0 (en) 11-desoxy-15-substituted-omega-pentanorprostaglandins and pharmaceutical compositions containing them
IL47761A (en) 9-hydroxy-19,20-bis-nor-prostanic acid and derivatives andpharmaceutical compositions containing them
IL47014A (en) Aminocarboxylic acid derivatgives,their reparation and pharmaceutical compositions containing them
IL48230A0 (en) Pharmaceutical compositions containing 2-naphthyl-butyric acid derivatives
IL50643A (en) 12-aza-11/oxo-9,9-dimethyl-15-hydroxy-prostanoic acid analogues their preparation and pharmaceutical compositions containing them
IL49952A0 (en) New dithiocarbamic acid esters,their preparation and pharmaceutical compositions containing them
IL51548A (en) Pharmaceutical compositions containing 4-hydroxy-2-quinolinone-3-carboxylic acid esters,certain such novel comounds and their preparation

Legal Events

Date Code Title Description
AT Record of annual fee payments

Year of fee payment: 13